• 国家科技部中国科技论文统计源期刊
  • 中国科技核心期刊
  • WHO西太平洋地区医学索引(WPRIM)收录期刊
  • 美国《化学文摘》收录期刊
艾塞那肽对肥胖及超重的中青年2型糖尿病患者体质量、血糖、血脂及蛋白尿的影响
Effects of Exenatide on Body Weight, Blood Glucose, Blood Lipids and Proteinuria in Obese and Overweight Young and Middle aged Patients with Type 2 Diabetes
投稿时间:2016-12-09  修订日期:2017-02-22
DOI:
中文关键词:  艾塞那肽  肥胖  超重  2型糖尿病
英文关键词:Exenatide  Obesity  Overweight  Type 2 diabetes
基金项目:
作者单位
朱巍 高秀莹 郭彩红 郭宝英 鲁辛 王瑞青 北京航天总医院内分泌科 北京 100076 
摘要点击次数: 335
全文下载次数: 291
中文摘要:
      摘 要 目的:探讨艾塞那肽对肥胖及超重的中青年2型糖尿病患者体质量、血糖、血脂、血同型半胱氨酸及蛋白尿的影响,为临床上更好地控制该类患者的大血管及微血管并发症提供依据。方法: 选取口服降糖药治疗不达标的肥胖及超重中青年2型糖尿病患者60例,随机分为艾塞那肽组 (n=30) 和诺和灵N组 (n=30),在维持原口服降糖药基础上,分别加用艾塞那肽和精蛋白生物合成人胰岛素(诺和灵N),疗程均为3个月。比较两组患者治疗前后的体质量、体质指数(BMI)、空腹血糖 (FPG)、餐后2h血糖 (2hPG)、糖化血红蛋白 (HbA1c)、空腹C肽 (FCP)、餐后2h C肽 (2hCP)、血脂、同型半胱氨酸 (HCY)及尿微量白蛋白 (UMA)等水平的变化。结果: 治疗3个月后,两组FPG、2hPG、HbA1c等指标均较治疗前明显下降 (P<0.05),且两组间相比无显著差异 (P>0.05)。艾塞那肽组患者的FCP、2hCP较治疗前升高 (P<0.05),体质量、BMI、TG、UMA均较治疗前显著下降 (P<0.05),且均明显优于诺和灵N组 (P<0.05);而诺和灵N组上述指标治疗前后无明显差异 (P>0.05)。结论:艾塞那肽能有效控制血糖,并且可明显减重、改善胰岛功能、降低血脂、降低尿蛋白。
英文摘要:
      ABSTRACT Objective: To investigate the effects of exenatide on body weight, blood glucose, blood lipids and proteinuria in obese and overweight young and middle aged patients with type 2 diabetes to provide reference for better controlling the macro vascular and micro vascular complications in the patients.Methods: Totally 60 obese and overweight young and middle aged patients with poorly controlled type 2 diabetes were chosen and randomly divided into exenatide group and novolin N group with 30 ones in each. The patients maintained the previous oral hypoglycemic drugs, and exenatide group was treated with exenatide, Novolin N group was treated with protamine biosynthetie human insulin(NovolinN), and the treatment course was 3 months. The body weight, BMI, fasting plasma glucose (FPG), 2 hour postprandial blood glucose (2hPG), glycated hemoglobin (HbA1C), fasting C peptide (FCP), 2 hour postprandial C peptide (2hCP), blood lipids, plasma homocysteine (HCY) and urine microalbumin (UMA) were compared before and after the treatment.Results:After 3 month treatment,the FPG,zhpG and HbAlc were significantly decreased both in exenatide group and NwoCinN group(P<0.05),and were no significant differences.were found in these parameters between the two groups(P>0.05). In exenatide group, the levels of FCP and 2hCP were higher than those before the treatment (P<0.05), and the body weight, BMI, TG and UMA were significantly lower than those before the treatment (P<0.05). However, in Novolin N group, all the above mentioned indices were not significantly changed after the treatment (P>0.05). Conclusion:Exenatide can effectively control blood glucose, improve β cell function, reduce body weight, lower blood lipids and decrease urine protein.
查看全文  查看/发表评论  下载PDF阅读器
关闭